ABBV-453
Sponsors
AbbVie
Conditions
Chronic Lymphocytic LeukemiaRelapsed/Refractory Multiple MyelomaSmall Lymphocytic Lymphoma
Phase 1
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
Active, not recruitingNCT05308654
Start: 2022-05-17End: 2025-12-31Updated: 2025-08-14
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Active, not recruitingNCT06291220
Start: 2025-01-27End: 2027-07-01Updated: 2026-09-11